X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (148) 148
Publication (18) 18
Book / eBook (2) 2
Dissertation (2) 2
Magazine Article (2) 2
Book Chapter (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
index medicus (62) 62
male (58) 58
female (53) 53
middle aged (46) 46
adult (36) 36
pharmacology & pharmacy (26) 26
aged (25) 25
animals (20) 20
diabetes (19) 19
pharmacokinetics (16) 16
care and treatment (15) 15
medicine & public health (15) 15
research (15) 15
endocrinology & metabolism (14) 14
young adult (13) 13
cardiovascular diseases (11) 11
dose-response relationship, drug (11) 11
double-blind method (11) 11
drug therapy, combination (11) 11
follow-up studies (11) 11
treatment outcome (11) 11
abridged index medicus (10) 10
analysis (10) 10
risk factors (10) 10
alectinib (9) 9
antiviral agents - administration & dosage (9) 9
carcinoma, non-small-cell lung - drug therapy (9) 9
clinical trials (9) 9
drug interactions (9) 9
health aspects (9) 9
internal medicine (9) 9
medicine, general & internal (9) 9
therapy (9) 9
antiviral agents - pharmacokinetics (8) 8
area under curve (8) 8
drug therapy (8) 8
glucose (8) 8
hepatitis c (8) 8
insulin (8) 8
lung neoplasms - drug therapy (8) 8
nf-kappa b - metabolism (8) 8
pharmacology/toxicology (8) 8
receptor for advanced glycation end products (8) 8
risk (8) 8
ritonavir (8) 8
type 2 diabetes (8) 8
carbazoles - pharmacokinetics (7) 7
cardiac & cardiovascular systems (7) 7
cardiovascular disease (7) 7
cell lung-cancer (7) 7
crizotinib (7) 7
cross-over studies (7) 7
genetic aspects (7) 7
genotype (7) 7
lactams - administration & dosage (7) 7
mice (7) 7
myocardial infarction (7) 7
oncology (7) 7
pharmacology (7) 7
piperidines - pharmacokinetics (7) 7
proportional hazards models (7) 7
ritonavir - administration & dosage (7) 7
sulfonamides - administration & dosage (7) 7
administration, oral (6) 6
adolescent (6) 6
antitumor-activity (6) 6
antiviral agents (6) 6
carbazoles - therapeutic use (6) 6
disease (6) 6
dosage and administration (6) 6
drug administration schedule (6) 6
expression (6) 6
glycation end-products (6) 6
hepacivirus - drug effects (6) 6
lactams - pharmacokinetics (6) 6
life sciences (6) 6
liver (6) 6
metabolism (6) 6
nitric oxide (6) 6
open-label (6) 6
oxidative stress (6) 6
patients (6) 6
physiological aspects (6) 6
piperidines - therapeutic use (6) 6
plasma (6) 6
proteins (6) 6
radiology, nuclear medicine & medical imaging (6) 6
receptor protein-tyrosine kinases - antagonists & inhibitors (6) 6
receptors, immunologic - metabolism (6) 6
ribavirin (6) 6
sulfonamides - pharmacokinetics (6) 6
cancer (5) 5
cancer research (5) 5
carbazoles - administration & dosage (5) 5
carbazoles - adverse effects (5) 5
cardiovascular diseases - prevention & control (5) 5
danoprevir (5) 5
diabetes mellitus, type 2 - blood (5) 5
diabetes mellitus, type 2 - complications (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 04/2019, Volume 105, Issue 4, pp. 826 - 828
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e21137 - e21137
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9751, pp. 1467 - 1475
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1119 - 1128
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2019, Volume 84, Issue 3, pp. 661 - 666
Journal Article
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 02/2014, Volume 52, Issue 2, pp. 103 - 111
Journal Article
International journal of clinical pharmacology and therapeutics, ISSN 0946-1965, 02/2014, Volume 52, Issue 2, p. 103
Danoprevir is a potent, highly selective, macrocyclic, orally bioavailable inhibitor of the hepatitis C virus protease, and a substrate of cytochrome P450... 
Area Under Curve | Humans | Middle Aged | Male | Ketoconazole - pharmacology | Sulfonamides - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Lactams - pharmacokinetics | Adult | Female | Ritonavir - pharmacology
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e20575 - e20575
Journal Article
Journal of Genetic Syndromes & Gene Therapy, 01/2015, Volume 6, Issue 1, pp. 1 - 1
Left ventricular non-compaction is an increasingly recognized familial cardiomyopathy characterized morphologically by deep myocardial trabeculations and a... 
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2018, Volume 82, Issue 1, pp. 129 - 138
Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated... 
Alectinib | Medicine & Public Health | ALK inhibitor | NSCLC | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Exposure response | HEALTHY-SUBJECTS | INHIBITOR ALECTINIB | ANTITUMOR-ACTIVITY | ER | MODELS | DRUGS | BRAIN METASTASES | PHARMACOLOGY & PHARMACY | MUTATIONS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Carbazoles - administration & dosage | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Anaplastic Lymphoma Kinase - genetics | Dose-Response Relationship, Drug | Multicenter Studies as Topic | Female | Lung Neoplasms - genetics | Carbazoles - adverse effects | Piperidines - administration & dosage | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Protein Kinase Inhibitors - administration & dosage | Crizotinib - pharmacology | Gene Rearrangement | Piperidines - adverse effects | Anaplastic Lymphoma Kinase - biosynthesis | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Clinical Trials, Phase II as Topic | Lymphomas | Metabolites | Lung cancer, Non-small cell | Analysis | Statistical analysis | Cell survival | Small cell lung carcinoma | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Exposure | Regression analysis | Cancer therapies | Patients | Lymphoma | Confidence intervals | Statistical models | Safety | Hazard assessment | Protein-tyrosine kinase | Cancer | Tumors | Original
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2018, Volume 58, Issue 12, pp. 1618 - 1628
Journal Article